Lawrence K. Cohen
Chief Executive Officer chez VIA PHARMACEUTICALS, INC.
Profil
Lawrence K.
Cohen's current job(s) include being the President & Chief Executive Officer at VIA Pharmaceuticals, Inc. since 2011, the Chief Executive Officer at Health2047, Inc. since 2017, and a Director at First Mile Care, Inc. Dr. Cohen's former job(s) include being the President & Chief Executive Officer at VIA Pharmaceuticals, Inc. from 2004 to 2007, the Chief Executive Officer at Zyomyx, Inc., the Vice President-Research & Development at Somatix Therapy Corp.
from 1988 to 1997, the Chief Operating Officer at Progenitor, Inc. from 1997 to 1998, and the Executive Vice President-Business Development at Kadmon Holdings, Inc. from 2014 to 2017.
Dr. Cohen's education history includes an undergraduate degree from Grinnell College and a doctorate degree from the University of Illinois.
Postes actifs de Lawrence K. Cohen
Sociétés | Poste | Début |
---|---|---|
VIA PHARMACEUTICALS, INC. | Chief Executive Officer | 05/06/2007 |
First Mile Care, Inc.
First Mile Care, Inc. Medical/Nursing ServicesHealth Services First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes. | Director/Board Member | - |
Health2047, Inc.
Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The private company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017. | Chief Executive Officer | 01/10/2017 |
Anciens postes connus de Lawrence K. Cohen
Sociétés | Poste | Fin |
---|---|---|
KADMON HOLDINGS, INC. | Corporate Officer/Principal | 20/10/2017 |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | President | 07/06/2007 |
Progenitor, Inc.
Progenitor, Inc. BiotechnologyHealth Technology Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH. | Chief Operating Officer | 01/01/1998 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Chief Tech/Sci/R&D Officer | 01/01/1997 |
Zyomyx, Inc.
Zyomyx, Inc. Medical SpecialtiesHealth Technology Zyomyx, Inc. manufactured point-of-care diagnostic devices based on cell-counting technology. It engaged in the development and commercialization of diagnostic platforms. The firm offered disposable CD4 T-cell, a point-of-care test for HIV and AIDS treatment. The company was founded by Peter Wagner, Steffen Nock, Christian Itin, and Dana Ault-Riche in 1998 and was headquartered in Fremont, CA. | Chief Executive Officer | - |
Formation de Lawrence K. Cohen
Grinnell College | Undergraduate Degree |
University of Illinois | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
VIA PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
Progenitor, Inc.
Progenitor, Inc. BiotechnologyHealth Technology Progenitor, Inc. is an American private company. The firm develops pharmaceutical compounds for nervous system. The company is headquartered in Columbus, OH. | Health Technology |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
Zyomyx, Inc.
Zyomyx, Inc. Medical SpecialtiesHealth Technology Zyomyx, Inc. manufactured point-of-care diagnostic devices based on cell-counting technology. It engaged in the development and commercialization of diagnostic platforms. The firm offered disposable CD4 T-cell, a point-of-care test for HIV and AIDS treatment. The company was founded by Peter Wagner, Steffen Nock, Christian Itin, and Dana Ault-Riche in 1998 and was headquartered in Fremont, CA. | Health Technology |
First Mile Care, Inc.
First Mile Care, Inc. Medical/Nursing ServicesHealth Services First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes. | Health Services |
Health2047, Inc.
Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The private company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017. | Finance |